McKesson Corporation (MCK) Income Statement

The 12% revenue growth for fiscal 2026 exceeded long-range targets, with 2026Q1 showing a 23.4% year-over-year spike, likely reflecting generic conversions and biosimilar adoption. However, the deceleration to 7.7% in 2027Q1 suggests a normalization from peak growth, though still above the historical mid-single-digit trend. Investors should monitor whether the RxTS segment can sustain its contribution to top-line momentum as the core distribution business remains inherently low-margin.

The structural gross margin of ~3.6% is typical for the distribution industry, but the sequential improvement in operating margin from 1.1% in 2026Q1 to 1.3% in 2027Q1 suggests cost discipline and a favorable mix shift toward specialty and technology services. The 2026Q4 operating margin of 2.3% stands out as an outlier, possibly due to one-time items or seasonal timing. Sustained margin expansion hinges on scaling RxTS and biosimilar volumes, which carry higher service fees than traditional generics.

The 30% operating income growth on 7.7% revenue growth in 2027Q1 suggests that McKesson is leveraging its fixed cost base, particularly in distribution and technology platforms. However, the 2026Q3 SG&A line was negative ($-2.0B), which appears to be a data anomaly or a significant one-time credit, warranting caution in interpreting that quarter's leverage. The consistent share repurchases have also amplified EPS growth, with adjusted EPS up 18% in fiscal 2026, but investors should distinguish between operational leverage and financial engineering.

The cost structure is heavily weighted toward inventory procurement, making gross margin highly sensitive to drug pricing and mix. SG&A efficiency has improved, with operating expenses growing slower than revenue, but the thin absolute margins mean any cost inflation in logistics or labor could disproportionately impact operating income. The negative SG&A in 2026Q3 is a data anomaly that should be disregarded, but it highlights the need for careful line-item review.

The fiscal 2026 results represent a clear inflection point, driven by the divestiture of European operations and increased focus on U.S. specialty and RxTS. The 2026Q4 operating margin of 2.3% was the highest in the ten-quarter period, suggesting that the mix shift is gaining traction. However, the subsequent quarter's margin decline to 1.3% indicates that this level may not be sustainable, and investors should watch whether the company can maintain this trajectory as it scales biosimilars and technology services.